Achieve life sciences reports financial results for first quarter 2023 and provides corporate update

Seattle and vancouver, british columbia, may 09, 2023 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced first quarter 2023 financial results and provided an update on the cytisinicline development program. recent business highlights released positive phase 2 orca-v1 clinical trial results showing statistically significant vaping cessation benefit for cytisinicline    announced accomplishment of key milestones, including last subject dosing and last subject visit, in the phase 3 orca-3 trial evaluating cytisinicline for smoking cessation   presented additional analyses from the phase 3 orca-2 trial at the society for research on nicotine and tobacco (srnt) annual meeting appointed three new members to achieve's board of directors “we are excited about our start to 2023, announcing statistically significant trial results from orca-v1 in april, and on-track to report topline results from the phase 3 orca-3 trial in the second quarter,” stated john bencich, chief executive officer of achieve.
ACHV Ratings Summary
ACHV Quant Ranking